"Moderna Stock Surges on Upgrades and Optimistic 2025 Sales Forecast"

Moderna Inc.'s stock surged by 10% after an upgrade to 'buy' from Oppenheimer, with analysts predicting approval for five of the company's products by 2026. Despite only having its COVID-19 vaccine currently approved, Moderna's promising pipeline includes vaccines for flu, RSV, and a cancer vaccine targeting melanoma. The upgrade follows a previous downgrade by Oppenheimer due to pipeline concerns, which have since been addressed. The company is expected to remain loss-making through 2026, but with a potential increase in sales from 2025 as education and awareness for vaccine boosters grow. The stock received a price target of $142, indicating over 30% potential upside.